Demineralized Bone Matrix Market Size, Share, Opportunities, And Trends By Product (Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate, Others), By Test Type (Low Serum Calcium Level Test, Blood Urea Nitrogen Test, Phosphate Level Test, Creatinine Value Test), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores), And By Geography - Forecasts From 2023 To 2028

The demineralized bone matrix market is estimated to grow at a CAGR of 4.39% during the forecast period.

The use of DBM in the spine has been studied in preclinical settings with encouraging outcomes. Clinical research on the impact of DBM on spinal fusion is sparse. For instance, in one research, firmly instrumented circumferential fusions using titanium mesh cages, coralline hydroxyapatite, and DBM were successful in achieving anterior interbody fusion of the lumbar spine.

Opportunities for the demineralized bone matrix market to increase

The demineralized bone matrix industry is anticipated to grow quickly due to developments in grafting techniques and an increase in aesthetic surgery. Athletes and the younger generation's increased need for surgical treatments and soft tissue allografts will surely propel this industry ahead.

Growing geriatric population

The key reason driving the expansion of the demineralized bone matrix market is the ageing population, which is more prone to fractures and bone degradation. Globally, the number of older individuals is rising quickly. By 2050, the Globe Health Organisation (WHO) projects that there will be 2.1 billion individuals in the globe who are 60 years of age or older. Age increases a person's risk of bone deterioration and fractures, and older people are more likely to have these disorders. Demineralized bone matrix is projected to see increased demand due to the ageing population's increased prevalence of these diseases, which will propel demineralized bone matrix market growth.

Rising prevalence of bone-related disorders

The demineralized bone matrix industry is expected to expand due in large part to the rising frequency of bone-related diseases and injuries as well as the rising number of dental treatments including bone grafting and dental implant surgeries for a variety of tooth ailments. The expansion of the demineralized bone matrix market is attributed to the increasing use and desire for minimally invasive operations. The advantages of minimally invasive surgery include reduced discomfort, fewer problems, and a quicker recovery. Minimally invasive methods employ demineralized bone matrix.

Enhancement in Technology

The recent expansion of the sector has been significantly attributed to technological developments including the development of biomimetic and implantable microcarriers that use a demineralized bone matrix and maintain the crucial biochemical composition, architecture, and surface topography of genuine bone tissue. In addition to improvements in materials, designs and allografting methods, which are employed in several difficult procedures, are regarded as a major development. The high cost of the demineralized bone matrix is a demineralized bone matrix market growth barrier which is being tackled by introducing cheaper alternatives.

Growing popularity in dental application

The dental application is anticipated to expand throughout the projected period. The increased growth rate is attributed to the dental surgeon's predilection for demineralized bone matrix materials during dental procedures. Furthermore, it is anticipated that this demineralized bone matrix market would expand quickly due to the rising number of training sessions for dental professionals offered by reputable organisations to increase awareness of DBM. Additionally, the availability of dentists with advanced training would support the demineralized bone matrix market growth.

High procedural volume at hospitals

The hospitals are anticipated to dominate the demineralized bone matrix market due to the greater number of bone graft treatments performed in hospitals for orthopaedic and dental procedures,. Hospitals in wealthy and developing nations both grant suitable reimbursement schemes. Additionally, hospitals are furnished with cutting-edge surgical tools and equipment. Since more patients are choosing hospitals for bone transplant surgeries, the hospital sector is predicted to grow. The demineralized bone matrix industry is also expected to experience astounding growth due to the rising availability of many medical services in hospitals throughout established and developing nations.

The market for demineralized bone matrices in North America is anticipated to expand quickly. 

Demineralized bone matrix sales in North America are anticipated to lead the global demineralized bone matrix market, and it is most probable that this trend will continue during the forecast period. The demineralized bone matrix market growth in the North American region is primarily driven by elements like the presence of sophisticated healthcare infrastructure and technological capabilities, the rising prevalence of bone-related disorders and orthopaedic surgeries, and favourable reimbursement policies for bone grafting procedures.

Asia Pacific is anticipated to hold the second-largest market share

Over the projected period, the Asia Pacific demineralized bone matrix market is predicted to develop the quickest. The Asia Pacific region is expected to see the fastest rate of growth after North America over the projected period due to reasons like its dense population, emerging economies, and rising demand for cutting-edge treatment alternatives. Additionally, the industry has grown as a result of advantageous government policies, including China's healthcare reform and the Indian government's permission for 100% foreign direct investment in the medical devices sector. These two nations are anticipated to drive the expansion of the regional demineralized bone matrix market.

Market Key Developments

• In October 2022, Legacy Demineralized Bone Matrix (DBM), a putty for filling voids or gaps in bony defects or traumatic injuries of the spine, pelvis, or extremities, has been fully released to the market and received its first implants, according to Orthofix Medical Inc.
• In September 2022, Ossifix Orthopaedics, a subsidiary of Umbra Applied Technologies Group Inc. introduced a novel demineralized bone matrix product.
• In March 2022, Demineralized bone matrix (DBM) is now available from nonprofit company MTF Biologics owing to a supply arrangement inked with Bone Biologics.

Segmentation:

• By Product
  • Sevelamer
  • Calcium-based Phosphate Binders
  • Iron-based Phosphate Binders
  • Lanthanum Carbonate
  • Others
• By Test Type
  • Low Serum Calcium Level Test
  • Blood Urea Nitrogen Test
  • Phosphate Level Test
  • Creatinine Value Test
• By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. HYPERPHOSPHATEMIA TREATMENT MARKET, BY PRODUCT

5.1. Introduction

5.2. Sevelamer

5.3. Calcium-based Phosphate Binders

5.4. Iron-based Phosphate Binders

5.5. Lanthanum Carbonate

5.6. Others

6. HYPERPHOSPHATEMIA TREATMENT MARKET, BY TEST TYPE

6.1. Introduction

6.2. Low Serum Calcium Level Test

6.3. Blood Urea Nitrogen Test

6.4. Phosphate Level Test

6.5. Creatinine Value Test

7. HYPERPHOSPHATEMIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

7.1. Introduction

7.2. Hospital Pharmacy

7.3. Retail Pharmacy

7.4. Online Stores

8. HYPERPHOSPHATEMIA TREATMENT MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES 

10.1. Kissei

10.2. SRIASS

10.3. Clarivate

10.4. Ardelyx

10.5. MIMS

10.6. Astellas Pharma

10.7. Cigna

10.8. Chugai Pharm

10.9. Mayo Clinic

Kissei

SRIASS

Clarivate

Ardelyx

MIMS

Astellas Pharma

Cigna

Chugai Pharm

Mayo Clinic